Evosep ApS. (11/18/25). "Press Release: Evosep Welcomes Nordic Capital as a Majority Shareholder to Accelerate Its Effort towards Clinical Proteomics". Odense.

	Organisation	Evosep ApS
	Organisation 2	Nordic Capital (SE)
	Group	Nordic Capital (Group)
	Product	liquid chromatography (LC)
	Product 2	mass spectrometry-based proteomics
	Index term	Evosep–Nordic Capital: investment, 202511 investment €na making Nordic Capital majority shareholder of Evosep
	Person	Bern, Morten (Evosep 202309– promoted to CEO joined recently as CCO before Thermo Fisher)
	Person 2	Agnblad, Jonas (Nordic Capital 202511 Partner + Co-Head of Nordic Capital Evolution advisory)

Evosep, a leading innovator in sample preparation and separation solutions for LCMS-based proteomics, and Nordic Capital, a premier private equity investor in healthcare and technology, today announced that Nordic Capital will become the majority owner of Evosep. This partnership will accelerate Evosep’s mission to make proteomics more accessible and impactful through cutting-edge workflows, advanced analytics, and
actionable insights.

Evosep’s technology enables high-throughput, robust, and reproducible LC-MS based proteomics workflows, driving efficiency and scalability for translational research and biopharma applications. By simplifying complex proteomics processes, Evosep empowers laboratories to deliver deeper biological insights and accelerate discoveries that benefit modern healthcare and life sciences.

Nordic Capital brings a proven track record of investing in and scaling high-growth companies within healthcare and technology. With deep roots in protein-based innovation through its previous various ownerships, Nordic Capital sees Evosep as the natural next step in advancing proteomics for clinical use. This strategic alignment will enable Evosep to expand globally and develop transformative solutions for researchers and clinicians.

“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase. Together, we aim to redefine how proteomics drives efficiency, quality, and insight across healthcare and life sciences,” said Morten Bern, Evosep’s CEO and continues, “Evosep’s mission remains set in stone, and customers can expect us to continue pushing forward the standardization of LCMS-based proteomics with impactful products and solutions.”

“We are very impressed by Evosep’s highly innovative and differentiated technologies to enable and enhance proteomics analysis. The company enjoys a strong and loyal backing in both academia and biopharma. Nordic Capital intends to leverage its significant expertise in diagnostics and life science tools to support Morten and his team in further expanding the company’s reach and product offering,” said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.

The transaction is expected to close in Q4 2025. Terms of the transaction were not disclosed.

J.P. Morgan Securities plc is serving as exclusive financial advisor to the sellers and Plesner Advokatpartnerselskab is serving as legal advisor. VOMA will remain invested.

###

For more information, please call +45 2633 2021, e-mail info@evosep.com, or visit www.evosep.com

About Evosep

Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than today’s alternatives. Information about Evosep is available at www.evosep.com.

The Evosep Eno is classified as General Laboratory Equipment.

About Nordic Capital

Nordic Capital is a leading international private equity investor and sub-sector specialist dedicated to building stronger, more sustainable businesses through operational improvement and transformative long-term growth in partnership with management teams. With over 35 years of experience, a global reach, and the local presence of dedicated sector investment advisory teams in Sweden, UK, Germany, Denmark, Norway, Finland and the US, Nordic Capital brings deep expertise across its core investment sectors: Healthcare, Technology & Payments, Financial Services and Services & Industrial Tech. Leveraging tailored playbooks, a dedicated operations advisory team and a global network of industrial and functional experts, Nordic Capital seeks to help companies to scale, innovate and become sustainable leaders. Nordic Capital currently manages around EUR 34 billion in assets and since its founding in 1989, has invested approximately EUR 30 billion in more than 150 middle-market companies in Northern Europe and North America. The committed capital is principally provided by global institutional investors such as pension funds. For more information, see www.nordiccapital.com or connect via LinkedIn.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

Media Contact Information:

Christian Ravnsborg
+ 45 26 33 20 21
cr@evosep.com

Billedskærervej 15
5230 Odense M
www.evosep.com

Record changed: 2025-12-15